-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Belite Bio, Lowers Price Target to $215

Benzinga·05/26/2026 17:25:27
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and lowers the price target from $223 to $215.